---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-064446"
form_type: "8-K"
ticker: "APUS"
cik: "0001894525"
company_name: "Apimeds Pharmaceuticals US, Inc."
filed_at: "2025-07-16T23:59:59+00:00"
generated_at: "2026-05-18T06:19:50.462705+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Apimeds appoints Dr. Susan Kramer SVP Development, Brian Peters to lead ai² division

## Summary
- Dr. Susan Kramer appointed SVP of Development; 30+ years experience including 18 at Genentech.
- Brian Peters joins as Head of ai² division; previously Chief Strategy & Insights Officer at Heller Agency.
- CEO Erik Emerson says strengthening operational leadership is a priority since IPO.
- Dr. Kramer will oversee all product development; Peters will lead ai² platform strategy and launch.
- Both appointments effective July 15, 2025.

## SEC filing metadata
- accession: 0001213900-25-064446
- form_type: 8-K
- ticker: APUS
- cik: 0001894525
- company_name: Apimeds Pharmaceuticals US, Inc.
- filed_at: 2025-07-16T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894525/000121390025064446/0001213900-25-064446-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894525/000121390025064446/ea0249160-8k_apimeds.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-064446
- JSON: https://secwatch.observer/filing/0001213900-25-064446.json
- Plain text: https://secwatch.observer/filing/0001213900-25-064446.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.